GSK Investigational Site

Ciudad Autonoma Buenos Aires C1430EGF

6 studies enrolling now · 15 studies all time

What they study most

Arthritis, Rheumatoid, Connective Tissue Diseases, Cough, HIV Infections, Infection, Human Immunodeficiency Virus, Lung Diseases, Interstitial, Lupus Nephritis, Neoplasms, Breast, Osteoarthritis, Knee, Pain, Refractory Chronic Cough, Scleroderma, Systemic

Studies at this site

• A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed — Recruiting now
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) — Recruiting now
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — Recruiting now
• A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease — Recruiting now
• A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease — Recruiting now
• A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) — Recruiting now
• A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 — Running, not enrolling
• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults — Running, not enrolling
• A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain — Stopped early
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease — Running, not enrolling
• Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) — Stopped early
• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) — Stopped early
• Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis — Completed
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) — Completed